当前位置: X-MOL 学术Oncogene › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Oncogene ( IF 8 ) Pub Date : 2019-11-18 , DOI: 10.1038/s41388-019-1106-x
Carolyn J Loveridge 1, 2 , Sarah Slater 2 , Kirsteen J Campbell 1, 2 , Noor A Nam 2, 3 , John Knight 2 , Imran Ahmad 1, 2 , Ann Hedley 2 , Sergio Lilla 2 , Peter Repiscak 2 , Rachana Patel 2 , Mark Salji 1, 2 , Janis Fleming 2 , Louise Mitchell 2 , Colin Nixon 2 , Douglas Strathdee 2 , Matthew Neilson 2 , Chara Ntala 1, 2 , Sheila Bryson 2 , Sara Zanivan 1, 2 , Joanne Edwards 1 , Craig N Robson 4 , Carl S Goodyear 5 , Karen Blyth 2 , Hing Y Leung 1, 2
Affiliation  

BRF1 is a rate-limiting factor for RNA Polymerase III-mediated transcription and is elevated in numerous cancers. Here, we report that elevated levels of BRF1 associate with poor prognosis in human prostate cancer. In vitro studies in human prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation whereas the transient downregulation of BRF1 reduced proliferation and mediated cell cycle arrest. Consistent with our clinical observations, BRF1 overexpression in a Pten-deficient mouse (PtenΔ/Δ BRF1Tg) prostate cancer model accelerated prostate carcinogenesis and shortened survival. In PtenΔ/Δ BRF1Tg tumours, immune and inflammatory processes were altered, with reduced tumoral infiltration of neutrophils and CD4 positive T cells, which can be explained by decreased levels of complement factor D (CFD) and C7 components of the complement cascade, an innate immune pathway that influences the adaptive immune response. We tested if the secretome was involved in BRF1-driven tumorigenesis. Unbiased proteomic analysis on BRF1-overexpresing PC3 cells confirmed reduced levels of CFD in the secretome, implicating the complement system in prostate carcinogenesis. We further identify that expression of C7 significantly correlates with expression of CD4 and has the potential to alter clinical outcome in human prostate cancer, where low levels of C7 associate with poorer prognosis.

中文翻译:

BRF1 加速前列腺肿瘤发生并扰乱免疫浸润。

BRF1 是 RNA 聚合酶 III 介导的转录的限速因子,在许多癌症中升高。在这里,我们报告 BRF1 水平升高与人类前列腺癌预后不良有关。在人前列腺癌细胞系中的体外研究表明,BRF1 的瞬时过表达增加了细胞增殖,而 BRF1 的瞬时下调减少了增殖并介导了细胞周期停滞。与我们的临床观察一致,BRF1 在 Pten 缺陷小鼠 (PtenΔ/Δ BRF1Tg) 前列腺癌模型中的过表达加速了前列腺癌的发生并缩短了生存期。在 PtenΔ/Δ BRF1Tg 肿瘤中,免疫和炎症过程发生了改变,中性粒细胞和 CD4 阳性 T 细胞的肿瘤浸润减少,这可以通过补体级联的补体因子 D (CFD) 和 C7 成分的水平降低来解释,这是一种影响适应性免疫反应的先天免疫途径。我们测试了分泌组是否参与了 ​​BRF1 驱动的肿瘤发生。对 BRF1 过度表达的 PC3 细胞的无偏蛋白质组学分析证实了分泌组中 CFD 水平的降低,这表明补体系统在前列腺癌发生中起作用。我们进一步确定 C7 的表达与 CD4 的表达显着相关,并有可能改变人类前列腺癌的临床结果,其中低水平的 C7 与较差的预后相关。对 BRF1 过度表达的 PC3 细胞的无偏蛋白质组学分析证实了分泌组中 CFD 水平的降低,这表明补体系统在前列腺癌发生中起作用。我们进一步确定 C7 的表达与 CD4 的表达显着相关,并有可能改变人类前列腺癌的临床结果,其中低水平的 C7 与较差的预后相关。对 BRF1 过度表达的 PC3 细胞的无偏蛋白质组学分析证实了分泌组中 CFD 水平的降低,这表明补体系统在前列腺癌发生中起作用。我们进一步确定 C7 的表达与 CD4 的表达显着相关,并有可能改变人类前列腺癌的临床结果,其中低水平的 C7 与较差的预后相关。
更新日期:2019-11-18
down
wechat
bug